



## Tranzyme Pharma to Report Fourth Quarter and Year-End 2011 Financial Results

RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it will host a conference call on Wednesday, February 29, 2012 at 8:30 am ET to discuss fourth quarter and year-end 2011 financial results. The Company will report fourth quarter and year-end 2011 financial results after the close of the market on Tuesday, February 28, 2012.

To participate in the live call, please dial (877) 670-9784 (U.S. and Canada) or (970) 315-0430 (international), five to ten minutes prior to the start of the call. A live audio webcast will also be available in the "Investors" section of the Tranzyme Pharma website, [www.tranzyme.com](http://www.tranzyme.com).

A replay of the conference call will be available beginning February 29, 2012 at 11:30 am ET and ending on March 7, 2012. Investors may listen to the replay by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), with the passcode 53107188. The webcast will also be archived for on-demand listening for 30 days at [www.tranzyme.com](http://www.tranzyme.com).

### About Tranzyme Pharma

Tranzyme Pharma is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 20 percent of adults worldwide are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, currently there are a limited number of safe and effective treatment options. Tranzyme is developing an intravenous drug, [ulimorelin](#), for patients in acute (hospital-based) settings, as well as an oral drug, [TZP-102](#), for chronic conditions. [Ulimorelin](#) is currently in Phase 3 clinical trials and [TZP-102](#) is currently in Phase 2b clinical trials. Together these product candidates target a significant underserved market. By leveraging its proprietary drug discovery technology, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.

CONTACT: Corporate Inquiries:

Susan Sharpe

Director, Corporate Communications

(919) 328-1109

[ssharpe@tranzyme.com](mailto:ssharpe@tranzyme.com)

Investor Inquiries:

David Carey

Lazar Partners, Ltd.

(212) 867-1768

[dcarey@lazarpartners.com](mailto:dcarey@lazarpartners.com)